Acurx Pharmaceuticals (ACXP) Receivables (2023 - 2026)

Acurx Pharmaceuticals' (ACXP) quarterly Receivables came in at $56313.0 in Q1 2026, up 16.31% on a QoQ basis from $48417.0 in Q4 2025.

Acurx Pharmaceuticals (ACXP) Receivables (2023 - 2026) Analysis & Trends

Acurx Pharmaceuticals (ACXP) has 4 years of Receivables data on file, last reported at $56313.0 in Q1 2026.

Quarterly Receivables changed N/A year-over-year to $56313.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56313.0 (changed N/A YoY) and the FY2025 annual result came in at $48417.0, down 5.3% from the prior year.
Receivables advanced to $56313.0 in Q1 2026, from $48417.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $129159.0 in Q4 2023 to a low of $40208.0 in Q2 2025.
A 4-year average of $64241.5 and a median of $51127.0 in 2024 frame the typical range for Receivables.
Annual changes were most pronounced in 2024 — Receivables plunged 60.42% — and 2025, when it decreased 5.3%.
Tracing ACXP's Receivables over 4 years: stood at $129159.0 in 2023, then slumped by 60.42% to $51127.0 in 2024, then declined by 5.3% to $48417.0 in 2025, then increased by 16.31% to $56313.0 in 2026.
The last three Receivables figures came in at $56313.0 (Q1 2026), $48417.0 (Q4 2025), and $40208.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	Acurx Pharmaceuticals	6.18 Mn	6.18 Mn	-	140,278.00

Download Data